Tourmaline Bio Inc <TRML.OQ> expected to post a loss of 88 cents a share - Earnings Preview
Tourmaline Bio Inc TRML.OQ TRML.O is expected to show no change in quarterly revenue when it reports results on March 13 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Tourmaline Bio Inc is for a loss of 88 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 1.5% in the last three months.
Wall Street's median 12-month price target for Tourmaline Bio Inc is $55.00, above its last closing price of $17.04.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.81 | -0.87 | -0.86 | Beat | 0.9 |
Sep. 30 2024 | -0.80 | -0.82 | -0.78 | Beat | 4.5 |
Jun. 30 2024 | -0.71 | -0.71 | -0.68 | Beat | 4.7 |
Mar. 31 2024 | -0.69 | -0.67 | -0.55 | Beat | 17.7 |
Dec. 31 2023 | -0.72 | -0.79 | -0.81 | Missed | -2.5 |
| |||||
Mar. 31 2023 | -2.90 | -3.50 | -5.40 | Missed | -54.3 |
This summary was machine generated March 14 at 12:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
